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Abstract
North America's first government sanctioned medically supervised injection facility (SIF) was
opened during September 2003 in Vancouver, Canada. This was in response to a large open public
drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health
outcomes among the city's injection drug users. Between December 2003 and April 2005, a
representative sample of 1,035 SIF participants were enrolled in a prospective cohort that required
completing an interviewer-administered questionnaire and providing a blood sample for HIV
testing. HIV infection was detected in 170/1007 (17%) participants and was associated with
Aboriginal ethnicity (adjusted Odds Ratio [aOR], 2.70, 95% Confidence Interval [95% CI], 1.84–
3.97), a history of borrowing used needles/syringes (aOR, 2.0, 95% CI, 1.37–2.93), previous
incarceration (aOR, 1.87, 95% CI, 1.11–3.14), and daily injection cocaine use (aOR, 1.42, 95% CI,
1.00–2.03). The SIF has attracted a large number of marginalized injection drug users and presents
an excellent opportunity to enhance HIV prevention through education, the provision of sterile
injecting equipment, and a supervised environment to self-inject. In addition, the SIF is an important
point of contact for HIV positive individuals who may not be participating in HIV care and
treatment.
Background
In response to a large open public drug scene, high rates
of HIV and hepatitis C transmission, fatal drug overdoses,
and poor health outcomes among injection drug users,
Vancouver established North America's first government
sanctioned medically supervised safer injection facility
(SIF) in September 2003 [1-3]. The SIF has been approved
as a three year scientific evaluation by Health Canada with
a predetermined set of outcomes to be evaluated through
a comprehensive prospective strategy [4,5]. Initial find-
ings from the evaluation have been published, including
evidence that the SIF has attracted a wide range of margin-
alized injection drug users (IDUs) [6,7], has reduced drug
related public disorder [8], and has been associated with
reduced syringe sharing [9,10].
With respect to HIV, the focus of the SIF to date, as with
other harm reduction initiatives, has been on reducing
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HIV transmission through the provision of sterile syringes
and providing a space where self-administered injections
can be conducted in a clean and controlled environment
[4,11]. It has been previously shown in this community
that HIV infection has a disproportional impact on injec-
tion cocaine users [12], women [13], and those of Aborig-
inal ethnicity [14], and efforts to specifically engage and
accommodate these groups at the SIF are ongoing. Given
the high representation of these groups at the SIF, it is
anticipated that attending the SIF will result in reduced
transmission of HIV.
The purpose of this analysis is to measure the prevalence
and correlates of baseline HIV among those who are using
the SIF. This information is important to determine if the
SIF could be used as a site for HIV related care and treat-
ment. This is also important in order to measure the lon-
gitudinal incidence of HIV transmission among those
using the SIF.
Methods
As part of a comprehensive evaluation strategy, a repre-
sentative cohort of SIF users (SEOSI) was recruited and
followed prospectively. The methods have been described
previously [5]. Briefly, the cohort includes SIF users who
were selected through a random number generation strat-
egy. Each week between 16 and 32 two-hour time blocks
were designated for recruitment between the opening
hours of 10:00 a.m. and 4:00 a.m. seven days per week.
During these random time periods 10 cards were distrib-
uted to consecutive SIF users who were invited to visit the
SEOSI cohort study office located one block from the SIF.
There was a CAN$20 compensation provided if they were
willing to participate in the prospective study following a
full explanation, providing a written informed consent,
completing an interviewer-administered questionnaire
and supplying a blood sample for HIV and hepatitis C
testing. All SEOSI participants provide informed consent
to link to the Insite database so that SIF use can be tracked,
as well as informed consent to access administrative
health record databases in the community. The study was
closed to new participants as of March 31, 2005 at which
time 1,035 people were enrolled in the cohort from 4,764
individuals who had ever visited the SIF. A comparison
between all SIF users and SEOSI cohort participants has
shown statistically similar socio-demographic variables
(all p > 0.5)[5]. The study was approved by the University
of British Columbia/Providence Health Care Ethics
Board.
To determine factors associated with HIV infection, bivar-
iate analysis was performed using Pearson's Chi-square
testing and Wilcoxon rank sum test. Logistic regression
analysis was also performed to examine factors that were
independently associated with HIV infection. The multi-
variable models were fit adjusting for variables that were
of interest a priori or that were statistically significant at
the p < 0.05 level in the bivariable analyses. The statistical
analysis was performed using SPSS 12.0, and all reported
p-values are two sided.
Results
This analysis includes data from the baseline recruitment
of 1,035 individuals who were randomly selected to par-
ticipate in the SEOSI cohort between December 1, 2003
and March 31, 2005. Of these, HIV testing was available
on 1007 (97%). The missing HIV results were attributed
to difficulty in obtaining venous blood samples from 28
of the participants. Among those tested, 170 of 1007
(17%) were found to be HIV positive. Table 1 shows the
demographic characteristics of the participants stratified
by HIV serostatus. In this bivariate comparison, HIV pos-
itive status was associated with more years of drug inject-
ing (p = 0.008), Aboriginal ethnicity (p < 0.001), daily
cocaine injecting (p = 0.020), borrowing used needles/
syringes (p < 0.001), methadone maintenance treatment
(p = 0.018), sex work (p = 0.051), and history of incarcer-
ation (p = 0.004). In this cohort, HIV infection was not
associated with gender, residence in the Vancouver's
Downtown Eastside, daily heroin injection, daily crystal
methamphetamine injection, public drug use, requiring
help with injecting, sharing other drug using equipment,
or binge drug use.
In the logistic regression analysis shown in Table 2, HIV
positive status was independently associated with Aborig-
inal ethnicity (adjusted Odds Ratio [aOR] 2.70, 95% Con-
fidence Interval [CI] 1.84, 3.97), borrowing used needles/
syringes (aOR = 2.00, 95% CI:1.37, 2.93), history of incar-
ceration (aOR = 1.87, 95% CI:1.11, 3.14), and daily
cocaine injection (aOR 1.42, 95% CI:1.00, 2.03).
Discussion
The overall HIV seroprevalence among a random cohort
of injection drug users attending the SIF was 17%. This
was not unexpected as high rates of HIV infection among
injection drug users has been reported in this community
for over a decade [1,12]. However, the random selection
process used to assemble this cohort may be more repre-
sentative of active injection drug users in this community
when compared with previous estimates that were based
on non-random recruitment. The variables associated
with HIV infection in this cohort; Aboriginal ethnicity,
borrowing used needles, incarceration, and cocaine use,
are consistent with characteristics previously described in
this population.
The disproportionately high HIV prevalence among Abo-
riginal people has been attributed to the convergence of
environmental, social and behavioral factors that increaseHarm Reduction Journal 2006, 3:36 http://www.harmreductionjournal.com/content/3/1/36
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vulnerability to illicit drug use and HIV infection [14,15].
Providing culturally relevant services for Aboriginal peo-
ple is a priority for this community as the uptake of serv-
ices and supports is suboptimal. In this context, it is
encouraging that the SIF has attracted a relatively large
number of Aboriginal people, and can provide an impor-
tant point of contact for those who may be reluctant to
participate in other health and social services.
The association between intensive cocaine use and HIV
infection has been well described in this community and
injection cocaine is consistently found to increase HIV
transmission [12,16]. The propensity of many IDUs to use
cocaine in high-intensity episodic patterns contributes to
the high risk of HIV transmission associated with cocaine
use [17]. This pattern of drug use may be particularly
influenced at the SIF as only one injection is allowed at
Table 1: Prevalence of HIV stratified by socio-demographic and behavioural variables.
Characteristic HIV-Positive n (%) HIV-Negative n (%) Odds Ratio (95% CI) p value
Age
Median (IQR) 37.9 (10.3) 38.6 (12.1) .914
Gender
Male 113 (66.5) 612 (73.1) 0.73 (0.51 – 1.04) .078
Female 57 (33.5) 225 (26.9)
Ethnicity
Aboriginal 55 (32.4) 140 (16.7) 2.38 (1.65 – 3.44) <.001
Other 115 (67.6) 697 (83.3)
Reside in DTES
Yes 120 (70.6) 570 (68.1) 1.12 (0.78 – 1.61) .524
No 50 (29.4) 267 (31.9)
Daily Cocaine Injection
Yes 68 (40.0) 258 (30.8) 1.50 (1.07 – 2.10) .020
No 102 (60.0) 579 (69.2)
Daily Heroin Injection
Yes 78 (45.9) 435 (52.0) 0.78 (0.56 – 1.09) .148
No 92 (54.1) 402 (48.0)
Daily Crystal Meth Injection
Yes 3 (1.8) 31 (3.7) 0.47 (0.14 – 1.55) .202
No 167 (98.2) 806 (96.3)
Public drug use
Yes 128 (75.3) 605 (72.3) 1.17 (0.80 – 1.71) .421
No 42 (24.7) 232 (27.7)
Ever borrow needles/syringes
Yes 122 (71.8) 455 (54.4) 2.13 (1.49 – 3.06) <.001
No 48 (28.2) 382 (45.6)
Share other equipment
Yes 104 (61.2) 477 (57.0) 1.19 (0.85 – 1.67) .314
No 66 (38.8) 360 (43.0)
Require help injecting
Yes 134 (78.8) 619 (74.0) 1.31 (0.88 – 1.95) .183
No 36 (21.2) 218 (26.0)
Binge drug use
Yes 109 (64.1) 525 (62.7) 1.06 (0.75 – 1.50) .732
No 61 (35.9) 312 (37.3)
Addiction Treatment
Yes 92 (54.1) 361 (43.1) 1.56 (1.12 – 2.17) .009
No 78 (45.9) 476 (56.9)
On Methadone Currently
Yes 48 (28.2) 168 (20.1) 1.57 (1.08 – 2.28) .018
No 122 (71.8) 669 (79.9)
Sex-trade Ever
Yes 78 (45.9) 317 (37.9) 1.39 (1.00 – 1.94) .051
No 92 (54.1) 520 (62.1)
History of incarceration
Yes 150 (88.2) 658 (78.6) 2.04 (1.24 – 3.35) .004
No 20 (11.8) 179 (21.4)
Note: IQR = inter-quartile range, DTES = Downtown EastsideHarm Reduction Journal 2006, 3:36 http://www.harmreductionjournal.com/content/3/1/36
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each visit. This may pre-empt a prolonged "drug-run" or
individuals may decide to use the SIF specifically as a way
to interrupt a current period of intensive drug use. Studies
are currently underway to better understand the impact
on the SIF on drug use patterns. These results however do
show that cocaine users do attend the SIF and that earlier
concerns that people would not use cocaine at the SIF
were unfounded [6].
A history of incarceration is often an indicator of social
isolation and the majority of convictions seen in this pop-
ulation are on the basis of illegal drug infractions. The
relationship between incarceration and increased HIV
transmission among injection drug users is a major area of
debate for Canada and globally [18]. In this cross-sec-
tional study, it is not possible to determine the date of HIV
infection and its temporal relationship with prior incar-
ceration, however there are risk behaviors that do occur
during the time of incarceration and more efforts to
reduce the harms to inmates are needed [19-21].
In addition to connecting with HIV positive people, the
SIF functions as an important entry point to provide pri-
mary HIV prevention. One of the primary objectives of the
SIF is to develop consistent contact with people at risk of
HIV who are often isolated and marginalized. The SIF
offers an engaging, low threshold environment and partic-
ipants are encouraged to attend regularly. During the vis-
its there is an opportunity to offer HIV prevention
education through the use of sterile injection techniques
and to emphasize the importance of clean needles as well
as opportunities for referral to addiction services includ-
ing counseling, detoxification, and methadone programs
[6].
It would be extremely unlikely to be exposed to HIV while
injecting at the SIF. All participants are supplied with new
needles/syringes, alcohol swabs, elastic tourniquets, and
cookers if required. All injections occurring within the SIF
are restricted to self-injections and this eliminates the high
risk behavior of people injecting each other [22]. How-
ever, this restriction will deter those who do require help
injecting from attending the SIF and strategies to reach
this group of IDUs are needed. Despite the high attend-
ance at the SIF, for many participants the majority of injec-
tions occur in other locations that may lead to risky drug
use practices. The site is currently operating at capacity
with approximately 700 visits per day. Increased hours of
operation (i.e. from 18 to 24 hours per day) and greater
capacity to accommodate more injection drug users
within the SIF would increase coverage.
There are a number of limitations with this study. The
cross-sectional nature of the analysis does not allow the
timing of HIV transmission to be determined and thus
some of the associated risks may have occurred after the
HIV infection. Secondly, some of the risk variables were
based on self-report and this may have been biased by
socially desirable responses. Thirdly, the participants in
the study were selected from those who had already made
a decision to use the SIF and are not necessarily represent-
ative of the injection drug using community.
Our results demonstrate a 17% prevalence of HIV infec-
tion among a representative cohort of IDUs who attend
Vancouver's SIF. The SIF has successfully attracted a group
of marginalized HIV infected individuals and therefore
provides a unique opportunity to improve access to
health services and HIV care and treatment [23]. Further-
more, the capacity to prevent new cases of HIV through
enhanced prevention messages and interventions at the
SIF has great potential. Many cities are confronting the
serious health and social consequences of poorly control-
led injection drug use among marginalized citizens and
subsequent outbreaks of HIV infection. The SIF in Van-
couver has provided a valuable addition to existing serv-
ices for injection drug users and should be considered in
other communities.
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Table 2: Multivariate Logistic Regression Analysis of Factors associated with baseline HIV Infection.
Characteristic Adjusted Odds Ratio 95% C.I. p-value
Aboriginal ethnicity
Yes vs No 2.70 1.84 – 3.97 <.001
Ever borrow needles/syringes
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History of incarceration
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